* arrhythmia
** pharmacotherapy
*** drug interactions
**** enzyme inducers
- Carbamazepine 
- Phenytoin 
- Phenobarbital
- Rifampin
- St. John’s Wort
**** enzyme inhibitors
- Amiodarone 
- Azithromycin/clarithromycin/erythromycin
- Cimetidine
- Diltiazem/verapamil 
- Fluconazole/ketoconazole 
- Fluoxetine/paroxetine 
- Quinidine
- Valproic acid
*** anti-arrhytmic drugs
**** Vaughan Williams classification
***** 1
****** CAST trial
class 1 anti-arrhythmics are considered unacceptable in patients without life-threatening ventricular arrhythmias
****** 1a :l:
******* Disopyramide
******* Quinidine
******* Procainamide
******** adverse effects
fatal blood dyscrasias
****** 1b :l:
******* Lidocaine
******* Mexiletine
******** brand
Mexitil
****** 1c :l:
******* Flecainide
******** contraindications
structural heart disease (CHD, HF, left ventricular hypertrophy, valvular heart disease)
******* Propafenone
******** brand
Rythmol
******** adverse effects
- bitter metallic taste
- risk of bronchospasm
******** contraindications
structural heart disease (CHD, HF, left ventricular hypertrophy, valvular heart disease)
***** 2
β-blockers
***** 3
****** common effect
increases QT interval, which may lead to TdP
****** drugs :l:
******* Amiodarone
******** brand
Cordarone
******** dose
- IV: 300 mg over 60 min then 20 mg/kg over 24 hr
- PO: 400 mg TID x5-7d until 10 g
******** unique property
long half life; 15-142 days
******** drug interactions
- Warfarin
- Digoxin
- Statins (max simvastatin dose 20 mg/day)
- Phenytoin ↑ ≥ 50%
- Lidocaine
******** black box warning
- Hepatotoxicity
- Pulmonary toxicity
******* Dofetilide
******** brand
Tikosyn
******* Dronedarone
******** brand
Multaq
******* Ibutilide
******** brand
Corvert
******* Sotalol
******** brand
Betapace
******** indication
rhythm control, /not/ rate control
***** 4 :l:
****** Verapamil
******* brands
- Calan
- Isoptin
- Verelan
****** Diltiazem
******* brands
- Cardizem
- Dilacor
- Tiazac
**** not clasified in Vaughan Williams
***** digoxin
****** brand
Lanoxin
****** dosing
- 0.5 mg IV
- 125-250 mcg PO
****** interactions
******* increased by
- amiodarone
- quinidine
- propafenone
******* decreased by
thyroid hormones
****** toxicity
visual disturbances—blue green halos
***** adenosine
****** brand
Adenocard
***** atropine
*** bradyarrhytmia
**** sinus bradycardia
***** treatment
atropine
*** tachyarrhytmia
**** supraventricular arrhytmias
*** atrial fibrillation/atrial flutter (AF/AFL)
**** drugs :l:
***** Metoprolol (Lopressor®)
***** Diltiazem
****** brand
Cardiazem
***** Digoxin
****** brands
- Lanoxin
- Digitek
- Digox
***** Amiodarone
****** brands
- Cordarone
- Nexterone
- Pacerone
**** rate control
- beta blockers
- CCBs
**** strategies for rythym control
***** structural heart disease
- amiodarone
- dofetilide
- dronedarone
- sotalol
***** no structural heart disease
- amiodarone
- dofetilide
- dronedarone
- sotalol
- flecainide
- propafenone
**** thromboembolism
***** CHA²DS²-VASc Score²
- Congestive heart failure: 1 point
- HTN: 1
- age ≥75: 2
- age 65-74: 1
- diabetes: 1
- prior stroke/TIA/TE: 2
- vascular disease: 1
- female: 1
***** DOACs :l:
****** dabigatran
******* brand
Pradaxa
******* adverse effects
- increased GI bleeding especially in elderly
- dyspepsia
******* dosing
150 BID
****** apixaban
******* brand
Eliquis
******* adverse effects
reduced GI bleeding
******* dosing
5 mg BID
****** rivaroxaban
******* brand
Xarelto
******* adverse effects
increased GI bleeding
******* dosing
15-20 mg QD
****** edoxaban
******* brand
Savaysa
******* dosing
60 mg QD
*** supraventricular tachycardia
**** acute
- adenosine (class I)
- IV diltiazem or verapamil (class IIa)
- IV beta blocker (class IIa)
**** maintenance
- diltiazem or verapamil
- beta blockers
- digoxin
*** ventricular arrhythmias
**** ventricular tachycardia
***** pharmacological
amiodarone
***** nonpharmacological
- catheter ablation
- implantable cardioverter-defibrilator (ICD)
- safer and more effective than pharmacological
**** TdP
* heart failure
** pharmacotherapy
*** acute decompensated heart failure
**** drugs
***** diuretics
****** thiazide :l:
******* scope
use as add on when not responding to loop diuretic
******* metolazone
******** dosing
2.5-5 mg PO QD
****** loop
******* scope
- most potent
- effective at CrCl <30
******* drugs :l:
******** furosemide
******** bumetanide
******** torsemide
***** vasopressin antagonists
****** when to use
Na <125 mmol/L
****** drugs :l:
******* Tolvaptan
******** brand
Samsca
***** inotropes :l:
****** dobutamine
******* MOA
- β1 agonist
- increases cAMP
- increases CO
****** milrinone
- mostly renally eliminated
******* brand
Primacor
******* MOA
- PDE inhibitor
- inhibits cAMP breakdown
- increases CO and decreases SVR
***** vasodilators :l:
****** nitroglycerin
******* adverse effects
- headache
- tachyphylaxis
****** nitroprusside
****** nesiritide
**** nonpharmacolologic
- sodium restricted diet; <2 g/day
- hyponatremia
- fluid restriction
- high sodium means brain could dry out
- ultrafiltration
* anemia
** pharmacology
*** definition
insufficient healthy RBCs to carry adequate oxygen to the body’s tissues
*** hematocrit
percent of a sample of whole blood occupied by intact RBCs
**** reference range
***** men
42-54%
***** women
38-46%
*** hematopoeisis
**** essential nutrients :l:
***** iron
***** folate
***** vitamin B12
****** storage
humans store vitamin B12, so deficiency can take a long time to show up
****** methyl-FH4 trapping
caused by B12 deficiency
**** erythropoietin
***** role
***** deficiency
*** drugs & ADRs
*** sickle cell anemia
**** defects in RBCs
**** drugs & ADRs
*** iron deficiency anemia
**** types :l:
***** microcytic
MCV <30
***** hypochromic
MCHC <30
***** reduced plasma ferritin
<12 µg/L
**** drugs
***** oral :l:
****** Ferrous salts (sulfate, gluconate, fumarate)
******* brands
- Feosol
- EzFe
******* adverse effects
- nausea
- constipation
- cramps
- diarrhea
- black stools
******* interaction
- vitamin C increases absorption
- shouldn’t be taken with antacids, milk, or whole grain cereals which reduce iron absorption
***** parenteral :l:
****** iron dextran, Sodium ferric gluconate iron sucrose
******* adverse effects
- headache
- fever
- nausea and vomiting
- anaphylaxis
** pharmacotherapy
*** morphology
**** macrocytic
***** megaloblastic
- folate deficiency
- B12 deficiency
***** non-megaloblastic
- Liver disease
- EtOH
- Endocrine
- Hemolysis
**** microcytic
- iron deficiency
- sickle cell anemia
**** normocytic
anemia of chronic disease (ACD)
*** iron deficiency anemia
**** causes
- inadequate absorption
- inadequate intake
- excess blood loss
- increased iron requirements
  - pregnancy
  - lactation
  - infants
  - rapid growth stages
**** management
***** iron replacement
****** dose
150-200 mg daily elemental iron in 2-3 divided doses (on an empty stomach) until H/H normalizes then continue 6 more months
***** outcomes
****** timetable
- hemoglobin should increase within 2-3 weeks
- 1-2 g/dL in first 2 weeks
****** monitoring
every 3-4 months for up to a year
***** drug interactions
****** iron decreases absorption
- fluoroquinolones
- Tetracycline and doxycycline 
***** drugs
****** intravenous
******* dose
1000 mg
******* common side effects
- flushing
******* drugs
******** iron detran
********* usage
must give test dose prior to administration because it has a black box warning for anaphylaxis
********* brand
Infed
******** sodium ferric gluconate
******** iron sucrose
******** ferumoxytol
******** ferric carboxymaltose
*** macrocytic anemia
**** vitamin B12 deficiency
***** oral treatment
cyanocobalamin 1000 mcg/day for life
**** folic acid deficiency
***** treatment
- rule out vitamin B12 deficiency because B12 is required for absorption of folic acid
- 0.4 - 1 mg PO daily
**** drug interactions
- methotrexate
  - avoid if methotrexate is given for CA
  - must give if methotrexate is given for RA
- increases metabolism of phenytoin
* fluid and electrolytes
** Sodium
*** reference range
136 mEq/L – 145 mEq/L
** Potassium
*** reference range
3.5 mEq/L– 5 mEq/L
*** hypokalemia
**** drug-induced
***** transcellular shift
- beta agonists
- insulin
- alkalosis
***** enhanced renal excretion
diuretics
***** enhanced fecal elimination
- Sodium polystyrene sulfonate (Kayexalate)
- Sodium zirconium cyclosilicate (Lokelma)
- Patiromer (Veltassa)
**** clinical presentation
- Muscle weakness
- Cardiac arrhythmias
- Rhabdomyolysis
- Increased digoxin toxicity
**** treatment
***** IV
****** KCl bolus
20 mEq/50 mL central line over 1 hour
*** hyperkalemia
**** TODO causes
***** via increasing K levels
***** via redistribution into ECF
**** signs and symptoms
- abnormal cardiac conduction
  - peaked, narrow T waves, wide QRS
  - can progress to VF and asystole
**** TODO treatment :l:
***** calcium gluconate
***** do not decrease potassium
** Magnesium
*** reference range
1.7 mg/dL – 2.3 mg/dL
*** hypomagnesemia
**** clinical presentation
- cardiovascular
  - torsades de points
  - arrhythmias
- digoxin toxicity
- neuromusuclar
** Calcium
*** reference range
8.5 mg/dL – 10.5 mg/dL
** Phosphorus
*** reference range
2.5 mg/dL – 4.5 mg/dL
